How does Setmelanotide (Imcivree) work?
Selective MC4R agonist. Activates the melanocortin-4 receptor in the hypothalamus, the appetite-control hub. In patients with rare loss-of-function mutations in this pathway, restoring the signal restores appetite regulation. In plain terms, Setmelanotide (Imcivree) is a weight-loss drug for rare genetic forms of obesity. An MC4R agonist, FDA-approved in 2020 for obesity due to POMC, PCSK1, or LEPR deficiency and in 2022 for Bardet-Biedl syndrome; it's the educational anchor for melanocortin-pathway weight regulation. Mechanistic detail like this comes largely from preclinical and early research, the human picture is limited.
What people use it for
- Patients with diagnosed monogenic obesity (POMC, PCSK1, LEPR, BBS)
- Educational reference for the MC4R pathway
- Researchers studying the melanocortin / hypothalamic appetite axis
References
- Setmelanotide for Obesity due to LEPR or POMC deficiency — Clément K et al., Lancet Diabetes Endocrinol, 2020
- Efficacy and safety of setmelanotide in patients with Bardet-Biedl syndrome and Alström syndrome: a phase 3 trial — Haqq AM et al., The Lancet Diabetes & Endocrinology, 2022
- Imcivree (setmelanotide) — Drugs@FDA approval record (ApplNo 213793) — FDA, Drugs@FDA
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Setmelanotide (Imcivree)
Last updated 2026-06-06.